Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397052 | 0.81 | ITGB1 (0.33) | ABCG2 | |
| SCHEMBL3392652 | 0.79 | KDM4C (0.34) | ABCG2DRD2DRD4DRD3 | |
| SCHEMBL2818087 | 0.79 | NPC1 (0.40) | ABCG2DRD2DRD4DRD3 | |
| SCHEMBL3396469 | 0.79 | ATR (0.33) | DRD4 | |
| SCHEMBL2816399 | 0.79 | AGTR1 (0.35) | ABCG2 | |
| SCHEMBL3395211 | 0.74 | ABCG2 (0.39) | ABCG2 | |
| SCHEMBL17941564 | 0.73 | LMNA (0.42) | DRD2DRD4DRD3 | |
| SCHEMBL1157284 | 0.70 | CYP4F2 (0.38) | DRD2DRD4DRD3 | |
| SCHEMBL17941589 | 0.69 | MAPT (0.41) | — | |
| SCHEMBL30655993 | 0.67 | BRD4 (0.36) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246348-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl)-biphenyl derivatives | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100152458-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7700784-B2 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152458-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES | AGTR1, AGTR2, AGT | ABCG2 496/4885DRD2 2913/4885DRD4 2592/4885 |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | AGTR1, AGTR2, AGT | ABCG2 1654/4885DRD2 4671/4885DRD4 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.